Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.36-0.08 (-1.08%)
At close: 04:00PM EST
7.30 -0.06 (-0.82%)
After hours: 05:04PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.44
Open7.43
Bid7.30 x 800
Ask7.40 x 1200
Day's Range7.35 - 7.61
52 Week Range2.54 - 86.95
Volume647,499
Avg. Volume2,239,839
Market Cap399.747M
Beta (5Y Monthly)0.44
PE Ratio (TTM)N/A
EPS (TTM)-3.10
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.56
  • GlobeNewswire

    Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

    – Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells –– AK007 potently blocks all known ligand interaction with Siglec-10, including the “don’t eat me” signal CD24 –– Monotherapy treatment with a Siglec-10 antagonist antibody polarized tumor-associated myeloid cells and reduced tumor burden in pre-clinical studies – SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology co

  • GlobeNewswire

    Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results

    SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2022. Recent Allakos Events Allakos’s lirentelimab clinical development is focused on atopic dermatitis and chronic spontaneous urticaria. Initiated a Phase 2b randomized,

  • Barrons.com

    Alkermes, Allakos, and Other Stocks See Action From Activist Investors

    Sarissa Capital disclosed a large stake in pharmaceutical firm Alkermes. New Enterprise Associates more than doubled its investment in clinical-stage drug firm Allakos.

Advertisement
Advertisement